Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Immunology
Disease Category: Rhinitis, Allergic, Perennial
Location: United States, FL
A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis
The objective of this study is to assess the efficacy and safety of 12 months of treatment with 300 IR of STG320 sublingual tablets compared with placebo in adults and adolescents with HDM-associated allergic rhinitis.
CW ID: 212080
Date Last Changed:
December 4, 2015
Main Inclusion Criteria:
Main Exclusion Criteria:
Protocol number: SL75.14
Renee SmithUniversity of South Florida- Asthma, Allergy, and Immunology Clinical Research Unit13801 Bruce B. Downs Blvd. #502Tampa, FL 33613Phone: 813-631-4024
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2017 CenterWatch.